Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma. - Wikidata - awgldk - TriplyDB

Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.

Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.

http://www.wikidata.org/entity/Q38957093

about

Mantle cell lymphoma concurrent with T-large granular lymphocytic leukemia: report of a case and review of literature Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199.Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.Molecular mechanisms of 2, 3', 4, 4', 5-pentachlorobiphenyl-induced thyroid dysfunction in FRTL-5 cells The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206 Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.Enhanced Anticancer Activity of PF-04691502, a Dual PI3K/mTOR Inhibitor, in Combination With VEGF siRNA Against Non-small-cell Lung Cancer Effect of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against human Merkel cell carcinoma MKL-1 cells OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.p70S6K promotes IL-6-induced epithelial-mesenchymal transition and metastasis of head and neck squamous cell carcinoma.Systems Perturbation Analysis of a Large-Scale Signal Transduction Model Reveals Potentially Influential Candidates for Cancer Therapeutics.Novel targeted therapeutics for mantle cell lymphoma--what's on the horizon?Assessing Metabolic Changes in Response to mTOR Inhibition in a Mantle Cell Lymphoma Xenograft Model Using AcidoCEST MRI.Targeting protein kinase C in mantle cell lymphoma.Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration.Activity of BKM120 and BEZ235 against Lymphoma Cells.Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities.The Role of Macrophage/B-Cell Interactions in the Pathophysiology of B-Cell Lymphomas.

P2860

Q26994777-86345B75-7BA6-4AAA-9111-CFE7CC2EE482 Q28075606-C7D06AAD-EF25-44E7-82CC-B88AB1C9155F Q30395557-C66B63D8-C104-4E7A-9140-6A3300BBFD11 Q33433009-71D9CD68-5A35-4291-8E1E-2B67A97FD232 Q35196612-E456A6F8-7E1C-4542-A1BB-EF467FD4EE71 Q35546455-00452CF3-4DD3-48E8-82AE-0BA67AC0411F Q35741623-D1668871-4B3B-4A15-B46F-E4D1C3E5B793 Q36192506-4AF12431-CD5D-45E6-A8FD-8068D525ECB0 Q36334756-C330CF66-4CCC-42E4-AA4F-76871FB0C641 Q36413415-CCDAE35B-F2C5-40FC-A5FB-30990D9B46A4 Q36725307-8BCE07D3-A13B-4892-B4E7-C588E5460556 Q37392765-1F139D21-292A-4863-904F-39A0279CE868 Q38366569-DC378013-60BE-47ED-B2C3-D1E4DCD6C17C Q38675161-D245A6CE-0A04-47B6-90D8-ED4C685F9DC6 Q38773520-162145F2-6B80-4402-846F-43676FB7C3DF Q38791124-BC114503-C991-43B5-87A8-A5DFF27079C0 Q38819975-D59835E2-A36C-41DF-91A7-96A6565A5F6B Q41855451-40E2EA91-09D0-49BE-8287-CAE76A9E4ABF Q46237281-D7D7FA7E-8761-4B41-AD24-340487C14CFE Q54957513-22185C9F-7638-471E-BCC8-FAF5E68FEC82

P2860

Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.

http://www.wikidata.org/entity/Q38957093

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Dual PI3K/mTOR inhibition is r ...... gnals in mantle cell lymphoma.

@en

type

label

Dual PI3K/mTOR inhibition is r ...... gnals in mantle cell lymphoma.

@en

prefLabel

Dual PI3K/mTOR inhibition is r ...... gnals in mantle cell lymphoma.

@en

P1433

Q38957093-D8B0BBBF-EA99-4FDB-89B6-E57FD745975F

P1476

Q38957093-502002EC-24FC-4864-977F-96532A69E796

P2093

Q38957093-3087702C-5DC2-4478-AA93-026DF6D23C8E

Q38957093-4EC81BA7-2DB3-4476-95E0-8B6A7EB0EF05

Q38957093-50D7F113-3699-462C-885D-F88EB9B08E06

Q38957093-5A4743A1-9FC4-4332-BFB8-650572353D2F

Q38957093-7D48367C-13EE-4F8B-92F7-17BDF1ECFA93

Q38957093-7FDEA3CE-2B9E-4EE9-95A5-B9E2118BE1CC

Q38957093-91938073-A2E9-44D0-9106-01F4A337BDBC

Q38957093-B746BBB0-B72F-4B90-A5CA-C0BC6A003D8D

P2860

Q38957093-07C72F39-A20F-480A-BE99-F1CA70714F47

Q38957093-0BFEAAC0-ECD4-4098-8E62-B6F21A565FAF

Q38957093-0C6A9D92-6A9C-491B-8A5A-887D28F3B367

Q38957093-152B1B87-064B-4BBD-A38B-B1F5323D8F94

Q38957093-1A210B8B-200F-460E-8C43-F1B3DCDCCFF9

Q38957093-2AE70A12-0021-4ED6-B163-5607D01E16B5

Q38957093-3343D569-382D-4089-9700-A4B1F67C1F4C

Q38957093-3B27DC16-9C80-4343-8AD9-07CE175EA783

Q38957093-3B7BC2AE-28C4-47DA-8927-A8B3136F095B

Q38957093-429B0824-77F3-4A28-8369-E1AB240AC40B

P304

Q38957093-18AD84A7-000A-47DF-B01F-7834366ABF5D

P31

Q38957093-0DD27CD6-E662-438F-B47A-9072B5C63E9B

P356

Q38957093-2297DEB3-C23E-4F50-A25B-A905EEDF7064

P407

Q38957093-2D38ED60-E862-4B5D-93B6-4B164F6CDB38

P433

Q38957093-7264850C-B5EC-4FB2-8DF8-2B6E2FD2B8D4

P478

Q38957093-221F367B-65CB-4ADF-B719-FE119870EE42

P50

Q38957093-10341809-4FC9-4079-8DB8-3A472F8C44DE

Q38957093-BD34FB2C-334F-438A-9792-B2B8BB98E066

Q38957093-CF24105C-D555-4522-B6C3-2225FBC52D58

Q38957093-F4036A87-6AE6-4BC2-BAB3-F580F9E153EA

P577

Q38957093-5B6DF0B9-1CE6-48DD-8050-2FC6A7C860A0

P698

Q38957093-3E7551EF-2615-4F7C-91AD-175DF7DAF4F4

P932

Q38957093-E46D377D-8B58-48DA-8054-D67D51314972

P356

ONCOTARGET.2253

P1433

P1476

Dual PI3K/mTOR inhibition is r ...... ignals in mantle cell lymphoma

@en

P2093

Arnau Montraveta

http://www.w3.org/2001/XMLSchema#string

Dolors Colomer

http://www.w3.org/2001/XMLSchema#string

Jocabed Roldán

http://www.w3.org/2001/XMLSchema#string

Laia Rosich

http://www.w3.org/2001/XMLSchema#string

Marta Aymerich

http://www.w3.org/2001/XMLSchema#string

Mónica López-Guerra

http://www.w3.org/2001/XMLSchema#string

Patricia Pérez-Galán

http://www.w3.org/2001/XMLSchema#string

Sílvia Beà

http://www.w3.org/2001/XMLSchema#string

P2860

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

Targeting the phosphoinositide 3-kinase pathway in cancer

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.

Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.

Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma.

P304

6788-6800

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.2253

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Itziar Salaverria

Sílvia Xargay-Torrent

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25216518

http://www.w3.org/2001/XMLSchema#string

P932

4196163

http://www.w3.org/2001/XMLSchema#string